Results 31 to 40 of about 1,335,871 (234)

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Non small-cell lung cancer with metastasis to thigh muscle and mandible: two case reports [PDF]

, 2013
INTRODUCTION: Lung cancer is the leading cause of cancer-related death in Europe and the US. Isolated metastases to skeletal muscle and the mandible are very uncommon. CASE PRESENTATION: This report presents two cases.
Agnese Montanino, Domingo Alberti, Fabrizio Cammarota, Francesca Maria Giugliano, Franco Fulciniti, Giampaolo De Palma, Giovanna Guida, Luciano Iadanza, Maria Mormile, Paolo Muto, Vincenzo Ravo   +10 more
core   +1 more source

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [PDF]

, 2004
BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).
Bell, D. W., Brannigan, B. W., Christiani, D. C., Gurubhagavatula, S., Haber, D. A., Haluska, F. G., Harris, P. L., Haserlat, S. M., Louis, D. N., Lynch, T. J., Okimoto, R. A., Settleman, J., Sordella, R., Supko, J. G.   +13 more
core   +1 more source

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +1 more source

The Diagnostic Accuracy of Chest CT in the Detection of Tumor and Nodal Status in Non Small Cell Lung Carcinoma [PDF]

, 2003
At this time there is an increasing demand for an accurate pre operative staging in non small cell lung cancer. Chest Computed Tomography (CT) is one of the imaging modality of choice used for this purpose.
Busroh, I. (Ismid), Icksan, A. (Aziza), Syachruddin, E. (Elisna), Yusuf, A. (Anwar)   +3 more
core   +1 more source

Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer [PDF]

, 2018
Lung cancer is the leading cause of death worldwide. The treatment choice for advanced stage of lung cancer may depend on histotype, performance status (PS), age, and comorbidities. In the present study, we focused on the effect of metronomic vinorelbine
Bruno, P, D'Ascanio, M, Fiorentino, C, Grieco, A, Mancini, R, Pezzuto, A, Ricci, A, Sposato, B   +7 more
core   +1 more source

Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer [PDF]

, 2014
BACKGROUND: Lung cancer is one of the leading causes of cancer death worldwide. Even with complete resection, the prognosis of early-stage non-small cell lung cancer is poor due to local and distant recurrence, and it remains unclear which biomarkers are
Hideki Ishihara, Hiroshi Kubo, Kazuya Uchino, Masahiro Yoshimura, Sachiyo Tada, Satoshi Suzuki, Takashi Kondo, Takashi Suzuki, Tomoko Matsushima   +8 more
core   +1 more source

Non-small cell lung cancer: early stages

Annals of Oncology, 2006
More than 170 000 new cases and 150 000 deaths have occurred in 2003 in US owing to lung cancer, which is the leading cancer death reason for men in US. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers [1, 2]. Despite the progress in imaging and diagnostic procedures, non-small cell lung cancer (NSCLC) usually presents as ...
Bria, Emilio, Ceribelli A, Trovò MG, Gelibter A, Gigante A, Calabrò E, Cuppone F, Cognetti F, Terzoli E, Pastorino U.   +9 more
openaire   +3 more sources

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer [PDF]

, 1921
IntroductionIt is unknown what type of interstitial lung disease (ILD) has high risk for chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD for patients with lung cancer with ILD.MethodsOne hundred nine patients ...
Kenmotsu, Hirotsugu, Naito, Tateaki, Kimura, Madoka, Ono, Akira, Shukuya, Takehito, Nakamura, Yukiko, Tsuya, Asuka, Kaira, Kyoichi, Murakami, Haruyasu, Takahashi, Toshiaki, Endo, Masahiro, Yamamoto, Nobuyuki   +11 more
core   +1 more source

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Drugs in Context, 2022
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro   +10 more
doaj   +1 more source